Carolyn Evan

Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer

Anis Hamid, Kathryn P. Gray, Grace Shaw et al. · European Urology · 2018 · 257 citations

Metastatic Prostate Cancer, Urology, Compound Genomic Alterations +6

Elevated IL‐8, TNF‐α, and MCP‐1 in men with metastatic prostate cancer starting androgen‐deprivation therapy (ADT) are associated with shorter time to castration‐resistance and overall survival

Jaya Sharma, Kathryn P. Gray, Lauren C. Harshman et al. · The Prostate · 2014 · 82 citations

Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry

Edoardo Francini, Kathryn P. Gray, Grace Shaw et al. · Prostate Cancer and Prostatic Diseases · 2019 · 74 citations · Full text

Urology, Oncology, Surgical Oncology +9

Development of an Integrated Prostate Cancer Research Information System

William Oh, J. D. Hayes, Carolyn Evan et al. · Clinical Genitourinary Cancer · 2006 · 71 citations

Urology, Medical Information System, Data Integration +3

Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease

Che‐Kai Tsao, Kathryn P. Gray, Mari Nakabayashi et al. · The Journal of Urology · 2015 · 69 citations